Btk inhibitors

1. A compound according to Formula I, or a pharmaceutically acceptable salt thereof

wherein:

R 1 is halogen;

R 2 is selected from the group consisting of

a) OH;

b) (1-6C)alkyl;

c) (3-6C)cycloalkyl;

d) (1-6C)alkoxy;

e) (1-3C)heterocycloalkyl; and

f) (1-3C)heteroaryl;

g) (2-4C)alkenyl; and

h) (2-4C)alkynyl;

R 2 is optionally substituted with one, two or three groups selected from: halogen, (1-6C)alkyl, (1-6C)alkoxy, hydroxy or cyano;

R 3 is H or (1-3C)alkyl;

R 2 and R 3 together can form a saturated heterocyclic 5- or 6-membered ring; and

x is 0 or 1.

2. The compound of claim 1 , wherein R 1 is fluorine.

3. The compound of claim 1 , wherein R 3 is CH 3 .

4. A compound selected from:

3-{(3R)-1-[(3-methyloxetan-3-yl)carbonyl]piperidin-3-yl}-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;

1-(4-phenoxyphenyl)-3-[(3R)-1-propanoylpiperidin-3-yl]-1H-pyrazolo[3,4-c]pyridin-7-amine;

3-[(3R)-1-(cyclopropylcarbonyl)piperidin-3-yl]-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;

3-{(3R)-1-[(2,2-difluorocyclopropyl)carbonyl]piperidin-3-yl}-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;

1-({(3R)-3-[7-amino-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-1-yl) carbonyl)cyclopropanol;

3-{(3R)-1-[(3,5-dimethylisoxazol-4-yl)carbonyl]piperidin-3-yl}-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;

3-[(3R)-1-(3-methoxypropanoyl)piperidin-3-yl]-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;

3-{(3R)-1-[(1-methylcyclopropyl)carbonyl]piperidin-3-yl}-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;

3-{(3R)-1-[(3,3-difluorocyclobutyl)carbonyl]piperidin-3-yl}-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;

1-({(3R)-3-[7-amino-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-1-yl}carbonyl)cyclopropanecarbonitrile;

3-[(3R)-1-(methoxyacetyl)piperidin-3-yl]-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;

3-[(3R)-1-(2-methylpropanoyl)piperidin-3-yl]-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;

3-[(3R)-1-(cyclobutylcarbonyl)piperidin-3-yl]-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;

3-[(3R)-1-acetylpiperidin-3-yl]-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;

3-{(3R)-1-[(2-methoxyethoxy)acetyl]piperidin-3-yl}-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;

3-[(3R)-1-(ethoxyacetyl)piperidin-3-yl]-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;

(2R)-1-{(3R)-3-[7-amino-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-1-yl}-1-oxopropan-2-ol;

(2S)-1-{(3R)-3-[7-amino-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-3-yl]piperidin-1-yl}-1-oxopropan-2-ol;

3-{(3R)-1-[(1-methyl-1H-imidazol-5-yl)carbonyl]piperidin-3-yl}-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;

3-{(3R)-1-[(1,4-dimethyl-1H-imidazol-5-yl)carbonyl]piperidin-3-yl}-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;

3-{(3R)-1-[(2S)-2-methoxypropanoyl]piperidin-3-yl}-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;

3-{(3R)-1-[(2R)-2-methoxypropanoyl]piperidin-3-yl}-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;

3-[(3R)-1-acryloylpiperidin-3-yl]-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;

3-[(3R)-1-but-2-ynoylpiperidin-3-yl]-1-(4-phenoxyphenyl)-1H-pyrazolo[3,4-c]pyridin-7-amine;

1-[4-(4-fluorophenoxy)phenyl]-3-{(3R)-1-[(3-methyloxetan-3-yl)carbonyl]piperidin-3-yl}-1H-pyrazolo[3,4-c]pyridin-7-amine;

(6R,8aS)-6-{7-amino-1-[4-(3-fluorophenoxy)phenyl]-1H-pyrazolo[3,4-c]pyridin-3-yl}hexahydroindolizin-3 (2H)-one;

1-[4-(3-fluorophenoxy)phenyl]-3-{(3R,6 S)-6-methyl-1-[(3-methyloxetan-3-yl)carbonyl]piperidin-3-yl}-1H-pyrazolo[3,4-c]pyridin-7-amine; and

(2R)-1-[(2S,5R)-5-{7-amino-1-[4-(3-fluorophenoxy)phenyl]-1H-pyrazolo[3,4-c]pyridin-3-yl}-2-methylpiperidin-1-yl]-1-oxopropan-2-ol;

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 or a pharmaceutically acceptable salt thereof for use in the treatment of Bruton's Tyrosine Kinase (Btk) mediated disorders.

6. A pharmaceutical composition which comprises the compound of claim 1 or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.

7. The pharmaceutical composition of claim 6 , which further comprises at least one additional therapeutically active agent.

8. A method for treating a subject suffering with a Bruton's Tyrosine Kinase (Btk) mediated disorder comprising administering to the subject the compound of claim 1 in an amount effective to treat the Btk mediated disorder, thereby treating the subject.

9. The method of claim 8 , wherein the Btk mediated disorder is selected from the group consisting of rheumatoid arthritis, psoriatic arthritis, infectious arthritis, progressive chronic arthritis, deforming arthritis, osteoarthritis, traumatic arthritis, gouty arthritis, Reiter's syndrome, polychondritis, acute synovitis and spondylitis, glomerulonephritis (with or without nephrotic syndrome), autoimmune hematologic disorders, hemolytic anemia, aplasic anemia, idiopathic thrombocytopenia, and neutropenia, autoimmune gastritis, and autoimmune inflammatory bowel diseases, ulcerative colitis, Crohn's disease, host versus graft disease, allograft rejection, chronic thyroiditis, Graves' disease, schleroderma, diabetes (type I and type II), active hepatitis (acute and chronic), pancreatitis, primary billiary cirrhosis, myasthenia gravis, multiple sclerosis, systemic lupus erythematosis, psoriasis, atopic dermatitis, contact dermatitis, eczema, skin sunburns, vasculitis, chronic renal insufficiency, Stevens-Johnson syndrome, inflammatory pain, idiopathic sprue, cachexia, sarcoidosis, Guillain-Barré syndrome, uveitis, conjunctivitis, kerato conjunctivitis, otitis media, periodontal disease, pulmonary interstitial fibrosis, asthma, bronchitis, rhinitis, sinusitis, pneumoconiosis, pulmonary insufficiency syndrome, pulmonary emphysema, pulmonary fibrosis, silicosis, chronic inflammatory pulmonary disease, and chronic obstructive pulmonary disease.

10. The method of claim 9 , wherein the Btk mediated disorder is rheumatoid arthritis, psoriatic arthritis, or osteoarthritis.